| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advanced CNA-informed fragmentomics enhances cross-cohort tumor detection
|
Grisolia Mrs, Piera
|
|
|
5 |
S |
p.
|
article
|
| 2 |
A first-line approach: Liquid biopsy-guided osimertinib therapy for EGFR-mutated NSCLC
|
Calabuig-Fariñas, Silvia
|
|
|
5 |
S |
p.
|
article
|
| 3 |
Algorithmic genomic alteration filtering and Circulating Tumor DNA (CTDNA) quantification in serial Liquid Biopsy (LBX) from patients with prostateccancer
|
Malapelle, Umberto
|
|
|
5 |
S |
p.
|
article
|
| 4 |
Analytical results of a tumor-informed digital droplet PCR approach for minimal residual disease
|
Klemantovich, Anna
|
|
|
5 |
S |
p.
|
article
|
| 5 |
An mDetect assay for monitoring treatment response in metastatic breast cancer patients
|
Frosst, Keira
|
|
|
5 |
S |
p.
|
article
|
| 6 |
A randomized trial of immune checkpoint inhibitor plasma proteomic biomarker and chemotherapy risk model in advanced non-small cell lung cancer
|
Singhal, Surbhi
|
|
|
5 |
S |
p.
|
article
|
| 7 |
Aspyre-lung blood: Validation of a simple, fast and Robust method for molecular profiling of actionable variants in plasma
|
Evans, Ryan
|
|
|
5 |
S |
p.
|
article
|
| 8 |
Assessing mutational status in NSCLC through exosomal liquid biopsies
|
Torres-Martínez, Susana
|
|
|
5 |
S |
p.
|
article
|
| 9 |
Assessing the performance of CFDNA extraction from plasma
|
Deans, Zandra
|
|
|
5 |
S |
p.
|
article
|
| 10 |
Association of circulating tumor DNA genotyping and computed tomography radiomics with clinical outcomes in patients with advanced NSCLC
|
Ranghiero, Alberto
|
|
|
5 |
S |
p.
|
article
|
| 11 |
Automated analysis pipeline for HER2 expression profiling in CTCS: Computational potential for advancing personalized therapy for metastatic breast cancer
|
Henretta, Sarah
|
|
|
5 |
S |
p.
|
article
|
| 12 |
BRAF V600 mutations detection in melanoma: A cross-methodological study using CFDNA
|
Lewintre, Eloisa Jantus
|
|
|
5 |
S |
p.
|
article
|
| 13 |
Cell-free RNA liquid biopsies uncover transcriptional networks underlying sepsis
|
Semenkovich, Nicholas
|
|
|
5 |
S |
p.
|
article
|
| 14 |
Cerebrospinal fluid circulating tumour DNA profiling for risk stratification and matched treatment for central nervous system metastases of NSCLCM metastases of NSCLC
|
Zheng, Meimei
|
|
|
5 |
S |
p.
|
article
|
| 15 |
Characterization of plasma cell free DNA variants as tumor-derived vs. Clonal Hematopoiesis of Indeterminate Potential (CHIP) in 11,457 cancer patients
|
Magee, Dan
|
|
|
5 |
S |
p.
|
article
|
| 16 |
Characterizing cell-free DNA from healthy Brca2-999del5 carriers
|
Einarsdóttir, Berglind Ósk
|
|
|
5 |
S |
p.
|
article
|
| 17 |
Characterizing the cell-free transcriptome in a humanized DLBCL patient-derived tumor xenograft model for RNA-based liquid biopsy in a preclinical setting
|
Decruyenaere, Philippe
|
|
|
5 |
S |
p.
|
article
|
| 18 |
Circulating T-cell receptor repertoire analysis improves cancer early detection
|
Yelensky, Roman
|
|
|
5 |
S |
p.
|
article
|
| 19 |
Circulating tumor DNA as part of the routine work-up for patients with suspected advanced lung cancer
|
Brasoveanu, Tia
|
|
|
5 |
S |
p.
|
article
|
| 20 |
Circulating tumor DNA (CTDNA) analysis for precision oncology: A tertiary oncology centre perspective in India
|
Shetty, Omshree
|
|
|
5 |
S |
p.
|
article
|
| 21 |
Circulating tumor DNA mutations as markers for brain metastases at diagnosis and during treatment
|
Paredes de la Fuente, Rodrigo
|
|
|
5 |
S |
p.
|
article
|
| 22 |
Circulating tumour cell isolation and enrichment for investigation of prostate cancer metastasis
|
Abusamra, Sophia
|
|
|
5 |
S |
p.
|
article
|
| 23 |
Clinical utility of body fluids for multiplexed detection of genetic alterations in cancer patients
|
Beatriz García, Beatriz
|
|
|
5 |
S |
p.
|
article
|
| 24 |
Comprehensive analysis of CTDNA and CTCS reveals resistance signatures and correlations with pet scan outcomes in cancer patients
|
Shafi, Gowhar
|
|
|
5 |
S |
p.
|
article
|
| 25 |
Comprehensive circulating cytokine/chemokine profiles for monitoring and predicting clinical outcomes in melanoma neoadjuvant immunotherapy
|
Roy, Dhruvajyoti
|
|
|
5 |
S |
p.
|
article
|
| 26 |
Computational Variant Origin Prediction (VOP) to distinguish germline, tumor somatic, and Clonal Hematopoiesis (CH) variants in Liquid Biopsy (LBX)
|
Pellini, Bruna
|
|
|
5 |
S |
p.
|
article
|
| 27 |
Contents
|
|
|
|
5 |
S |
p.
|
article
|
| 28 |
CTDNA-based detection of homologous recombination deficiency in MCRPC patients
|
Vlachos, Georgios
|
|
|
5 |
S |
p.
|
article
|
| 29 |
DEGS analysis of Circulating Tumor Cells (CTCS) and tissue tumor cells in Costa Rican HER2 positive metastatic breast cancer patients
|
Chinchilla-Monge, Ricardo
|
|
|
5 |
S |
p.
|
article
|
| 30 |
Detection of circulating tumor DNA after stereotactic ablative radiotherapy in patients with unbiopsied lung tumors (SABR-Detect)
|
Verma, Saurav
|
|
|
5 |
S |
p.
|
article
|
| 31 |
Detection of CTDNA after neoadjuvant chemotherapy predicts distant relapse-free survival, local and distant recurrence in TNBC: Findings from Tricia study
|
Roseshter, Talia
|
|
|
5 |
S |
p.
|
article
|
| 32 |
Determination of tumor PSMA expression and lutetium-PSMA response in men with prostate cancer using a novel epigenomic liquid biopsy platform
|
Ravi, Praful
|
|
|
5 |
S |
p.
|
article
|
| 33 |
Developing novel primary reference materials to support standardisation in liquid biopsy
|
Lo Cascio, Leandro
|
|
|
5 |
S |
p.
|
article
|
| 34 |
Development of an expert consensus on the clinical utility of circulating tumor cells in solid tumors
|
Nicolò, Eleonora
|
|
|
5 |
S |
p.
|
article
|
| 35 |
Discovering new markers to optimize the detection of circulating tumor cells
|
Mehtar, Amira
|
|
|
5 |
S |
p.
|
article
|
| 36 |
Discover: Plasma testing in patients with advanced undergenotyped NSCLC and in targeted therapy resistance
|
Alghabban, Abdulrahman
|
|
|
5 |
S |
p.
|
article
|
| 37 |
Downstream effector mutations indicate potential tyrosine kinase inhibitor resistance in EGFR mutated lung cancer patients
|
Shafi, Gowhar
|
|
|
5 |
S |
p.
|
article
|
| 38 |
Economic and clinical impact of integrating the PROphetNSCLC plasma proteomic test in MNSCLC treatment
|
Elon, Yehonatan
|
|
|
5 |
S |
p.
|
article
|
| 39 |
Enhancing sensitivity of CTDNA copy number detection by increasing plasma sample volume
|
Jafari, Nafiseh
|
|
|
5 |
S |
p.
|
article
|
| 40 |
ESR1 CTDNA testing in HR+/HER2 metastatic breast cancer: A real-world perspective from a referral laboratory
|
Venetis, Konstantinos
|
|
|
5 |
S |
p.
|
article
|
| 41 |
Evaluation of a new vacuum blood collection tube for cell-free DNA
|
Komai, Kuniya
|
|
|
5 |
S |
p.
|
article
|
| 42 |
Evaluation of full spectrum cell-free RNA in peripheral blood as potential biomarker for acute myeloid leukemia disease profiling
|
Thakral, Deepshi
|
|
|
5 |
S |
p.
|
article
|
| 43 |
Expanding clinical impact of liquid biopsy beyond genomics: exploration of novel epigenomic applications
|
Alshurafa, Hashem
|
|
|
5 |
S |
p.
|
article
|
| 44 |
Expanding the Impact of Liquid Biopsies in patients with newly diagnosed advanced lung cancer (Expandinglung)
|
Ahmed, Amina
|
|
|
5 |
S |
p.
|
article
|
| 45 |
Expert opinion recommendations for external quality assessment for liquid biopsy testing from the European liquid biopsy society CTDNA workshop
|
Zandra Deans,
|
|
|
5 |
S |
p.
|
article
|
| 46 |
Exploratory analysis of CTDNA and imaging response in Phase I/II chorus study of canakinumab with chemoradiation and durvalumab for NSCLC
|
Charalambous, Karmelina
|
|
|
5 |
S |
p.
|
article
|
| 47 |
Expression of programmed death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients
|
Khandare, Jayant
|
|
|
5 |
S |
p.
|
article
|
| 48 |
External quality assurance for circulating free (cfDNA) testing in prostate cancer: Observations and future perspectives
|
Maqsood, Arfa
|
|
|
5 |
S |
p.
|
article
|
| 49 |
Fluorescent DCFPYL (GUL-CY5) for detecting circulating tumor and immune cells containing cancer extracellular vesicles in early metastatic prostate cancer prognostication
|
Alawamry, Omar
|
|
|
5 |
S |
p.
|
article
|
| 50 |
Genomic-epigenomic CTDNA testing in metastatic breast cancer patients with no evidence of disease: Potential clinical utility from real-world data
|
Gianni, Caterina
|
|
|
5 |
S |
p.
|
article
|
| 51 |
GFAP, UCH-L1, TAU AND NFL as potential biomarkers for glioblastoma diagnosis and monitoring: A retrospective study
|
Decarpentrie, Jonathan
|
|
|
5 |
S |
p.
|
article
|
| 52 |
High-sensitivity detection and broad genomic profiling in HR+/HER2- breast cancer: Final comparative results using targeted single-gene and broad-panel sequencing assays
|
Balic, Marija
|
|
|
5 |
S |
p.
|
article
|
| 53 |
Identification of genomic features associated with CTDNA shedding in non-small cell lung cancer
|
Di Lello, Anna
|
|
|
5 |
S |
p.
|
article
|
| 54 |
Identification of tumor-marker gangliosides in serum for early-stage cancer diagnosis
|
Culp-Hill, Rachel
|
|
|
5 |
S |
p.
|
article
|
| 55 |
Impact on the therapeutic decision of Massive Gene Sequencing (NGS) in plasma from patients with advanced cancer.
|
Fernández-Murga, Leonor
|
|
|
5 |
S |
p.
|
article
|
| 56 |
ISLB 2024 Author Index
|
|
|
|
5 |
S |
p.
|
article
|
| 57 |
Liquid biopsy-derived proteomic signature for tailoring non-small cell lung cancer immunotherapy strategies
|
Harel, Michal
|
|
|
5 |
S |
p.
|
article
|
| 58 |
Liquid biopsy detection of gene Copy Number (CN) losses including existing and emerging clinical targets
|
Rolfo, Christian
|
|
|
5 |
S |
p.
|
article
|
| 59 |
Liquid biopsy for monitoring response in KRAS-mutated NSCLC patients treated with first-line immunotherapy
|
Munera-Maravilla, Ester
|
|
|
5 |
S |
p.
|
article
|
| 60 |
Liquid biopsy in real-life: Experience of a cancer center collecting camples from multiple institutions in An Italian Regional cancer network
|
Sacco, Gianluca
|
|
|
5 |
S |
p.
|
article
|
| 61 |
Methylation based CTDNA serial monitoring correlates with immunotherapy response in non-small cell lung cancer
|
Hsiao, Angela
|
|
|
5 |
S |
p.
|
article
|
| 62 |
Microorganosphere (MOS): A novel technology for Circulating Tumor Cell (CTC)-derived organoid formation
|
Molteni, Elisabetta
|
|
|
5 |
S |
p.
|
article
|
| 63 |
Minimally invasive image guided percutaneous lung nodule resection for definitive diagnosis and treatment of lung cancer
|
Fischel, Richard
|
|
|
5 |
S |
p.
|
article
|
| 64 |
Monitoring GALNT13 in blood of NSCLC patients with serial evaluation using digital RT-PCR. A Potential new liquid biopsy biomarker
|
Fernández Armúa, QF. Eugenia
|
|
|
5 |
S |
p.
|
article
|
| 65 |
Multimodal urine-based accurate and non-invasive tool for predicting immunotherapy response in bladder cancer
|
Martín de Bernardo, Álvaro
|
|
|
5 |
S |
p.
|
article
|
| 66 |
Multimomics analysis in longitudinal series of plasma samples of P.G12NSCLC patients under target treatment
|
Pepe, Francesco
|
|
|
5 |
S |
p.
|
article
|
| 67 |
Next gen liquid biopsy: Comprehensive analysis from a single tube of blood
|
Ladd, Jon
|
|
|
5 |
S |
p.
|
article
|
| 68 |
Non-invasive immunogram to characterize and monitor immune status in non-small cell lung cancer patients treated with immunotherapy.
|
Moreno-Manuel, Andrea
|
|
|
5 |
S |
p.
|
article
|
| 69 |
Novel technology affords Real-Time PCR the sensitivity required for minimal residual disease monitoring
|
Stischer, Mary
|
|
|
5 |
S |
p.
|
article
|
| 70 |
NSCLC exosomes: Unlocking biomarker potential
|
Torres-Martínez, Susana
|
|
|
5 |
S |
p.
|
article
|
| 71 |
Optimization and evaluation of a Novel CTC culture protocol using ‘Reset’ Vascular Endothelial Cells (R-VECS) and microfluidic enrichment
|
Bayou, Nadia
|
|
|
5 |
S |
p.
|
article
|
| 72 |
Optimizing high-quality RNA retrieval from dried blood microsamples for RNA sequencing
|
Ramos Varas Miss, Elena
|
|
|
5 |
S |
p.
|
article
|
| 73 |
PAN-CANCER ANALYSIS OF PRE-TREATMENT CIRCULATING TUMOR DNA (CTDNA) IN PATIENTS FROM THE PRINCESS MARGARET LIQUID BIOPSY PROGRAM
|
Strum, Scott
|
|
|
5 |
S |
p.
|
article
|
| 74 |
Pioneering South florida's first minority-focused breast cancer biorepository: Leveraging liquid biopsy, NGS, and CTDNA for advancements in precision medicine
|
Alvarez Pinzon, Andres
|
|
|
5 |
S |
p.
|
article
|
| 75 |
Potential of circulating micrornas as biomarkers in perioperative management of lung cancer
|
Samejima, Joji
|
|
|
5 |
S |
p.
|
article
|
| 76 |
Predicting genitourinary cancer tissue-of-origin using urine cell-free DNA fragmentomic features
|
Chauhan, Pradeep
|
|
|
5 |
S |
p.
|
article
|
| 77 |
Real world circulating tumor DNA detection in advanced pan-cancers by timing of liquid biopsy relative to therapy
|
Subbiah, Vivek
|
|
|
5 |
S |
p.
|
article
|
| 78 |
Real-world experience of the decentralized MSK-ACCESS powered with SOPHiA DDM solution
|
Klemm, Florian
|
|
|
5 |
S |
p.
|
article
|
| 79 |
Smart biosurface® technology for prostate cancer detection and risk stratification through CTC enumeration and biomarker expression profiling
|
Senic-Matuglia, Francesca
|
|
|
5 |
S |
p.
|
article
|
| 80 |
The survive study - Liquid biopsy guided surveillance in intermediate- to high-risk early breast cancer
|
Pipinikas, Christodoulos
|
|
|
5 |
S |
p.
|
article
|
| 81 |
Transforming the lung cancer diagnostic pathway with liquid biopsy: Early genomic results from the QuicDNA biomarker study in wales
|
Dodds, Rachel
|
|
|
5 |
S |
p.
|
article
|
| 82 |
Transit of Circulating Tumor Cells (CTC) POST radiotherapy at irradiated tumor regions in pan-cancer patients
|
Khandare, Jayant
|
|
|
5 |
S |
p.
|
article
|
| 83 |
Trends in physician perception and use of liquid biopsy in NSCLC within the US
|
Bender, Hope
|
|
|
5 |
S |
p.
|
article
|
| 84 |
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
|
Berntsen, Tam
|
|
|
5 |
S |
p.
|
article
|
| 85 |
Unlocking the full potential of liquid biopsy: A polymer method for the reagent-free recovery and storage of DNA from biofluids
|
Owens, Matthew
|
|
|
5 |
S |
p.
|
article
|
Journal description